Illumina to Buy Pacific Biosciences for $1.2 Billion
Illumina to Buy Pacific Biosciences for $1.2 Billion
The purchase adds long-read sequencing to Illumina’s portfolio.
Illumina to Buy Pacific Biosciences for $1.2 Billion
Illumina to Buy Pacific Biosciences for $1.2 Billion

The purchase adds long-read sequencing to Illumina’s portfolio.

The purchase adds long-read sequencing to Illumina’s portfolio.

biobusiness
The UK Pharmaceutical Industry Braces for Brexit
The UK Pharmaceutical Industry Braces for Brexit
Diana Kwon | Oct 12, 2018
As Britain’s departure date from the European Union approaches, drugmakers are preparing for potential changes to regulatory procedures and border controls.
Startups Plan the Health Data Gold Rush
Startups Plan the Health Data Gold Rush
Shawna Williams | Oct 1, 2018
Companies are building platforms based on blockchain technology to let individuals control and directly profit from their genomic and medical information.
Bringing the Internet of Things into the Lab
Bringing the Internet of Things into the Lab
Abby Olena | Jun 1, 2018
The IoT can link up many facets of research—from laboratory equipment to ideas—but scientists must be ready for the questions its implementation could raise.
Patent On Autism Genetic Test May Stifle Science
Patent On Autism Genetic Test May Stifle Science
Jessica Wright | May 30, 2018
LabCorp might be able to charge a licensing fee to any scientists who wish to sequence the gene HOMER1 in people who may have autism.
New Treatments for Phenylketonuria Aim to Loosen Reins on Strict Diet
New Treatments for Phenylketonuria Aim to Loosen Reins on Strict Diet
Diana Kwon | May 29, 2018
Biotechs have developed enzyme replacements and genetically modified probiotics to treat patients with the rare metabolic disorder.
Women Less Successful When Applying for Patents
Women Less Successful When Applying for Patents
Diana Kwon | Apr 18, 2018
An investigation of 2.7 million patent submissions in the U.S. finds gender disparities throughout the application process.
PARP Inhibitors Are Improving the Outlook of Hard-to-Treat Cancers
PARP Inhibitors Are Improving the Outlook of Hard-to-Treat Cancers
Vicki Brower | Apr 1, 2018
With three recent FDA approvals, and a number of Phase 3 trials ongoing, the drugs are seeing a surge in interest.
SEC Charges Theranos With Fraud
SEC Charges Theranos With Fraud
Jim Daley | Mar 14, 2018
The company raised more than $700 million based on false claims to investors, according to the complaint.
Sanofi and Celgene Spend $20 Billion in Major Biotech Acquisitions
Sanofi and Celgene Spend $20 Billion in Major Biotech Acquisitions
Katarina Zimmer | Jan 23, 2018
Pharmaceutical giant Sanofi to take over hemophilia drugmaker Biovertiv, while Celgene will buy cancer drugmaker Juno Therapeutics.